Q-omics provides the consensus-scored CGB5 profile across patient tissues and cancer cell-line models. CGB5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CGB5 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, CGB5 RNA expression shows 5,062 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight STAD, HNSC, and KIRC as cancer lineages where CGB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CGB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CGB5 survival associations across molecular data types. CGB5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CGB5 RNA expression–survival associations across cancer types. High CGB5 expression shows unfavorable associations in STAD, KIRC, ACC, LIHC and PAAD, but favorable associations in ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CGB5 RNA expression.
This table summarizes CGB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CGB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CGB5 shows higher tumor expression in HNSC, BLCA, LUAD, COAD, LUSC and ESCA. The HNSC box plot shows higher CGB5 RNA expression in tumor versus normal tissue (log2 FC = +0.397, t-test p = .001).
This table shows molecular features associated with CGB5 in patient tissues and cancer cell lines. In patient samples, CGB5 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, CGB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT.
